Optimal combination of seven tumour markers in prediction of advanced stage at first examination of patients with non-small cell lung cancer

Anticancer Research

Volumn 21, Issue 4 B, 2001, Pages 3085-3092

  Ando, S ^a   Kimura, H ^a   Iwai, N ^a   Nomoto, Y ^a   Shima, M ^a   Ando, M ^a   Kuriyama, T ^a  

^a CHIBA CANCER CENTER   (Japan)

Author keywords

At first medical examination; CA125; CEA; CYFRA; Lung adenocarcinoma; The prediction of advanced stage

Indexed keywords

ALPHA FETOPROTEIN; CA 125 ANTIGEN; CA 19-9 ANTIGEN; CARCINOEMBRYONIC ANTIGEN; CYTOKERATIN 19 FRAGMENT; NEURON SPECIFIC ENOLASE; SQUAMOUS CELL CARCINOMA ANTIGEN; TUMOR MARKER;

ADULT; ADVANCED CANCER; AGED; ARTICLE; CANCER DIAGNOSIS; CANCER STAGING; CONTROLLED STUDY; FEMALE; HUMAN; LUNG ADENOCARCINOMA; LUNG NON SMALL CELL CANCER; LUNG SQUAMOUS CELL CARCINOMA; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL;

ADENOCARCINOMA; ADULT; AGED; AGED, 80 AND OVER; ALPHA-FETOPROTEINS; ANTIGENS, NEOPLASM; CA-125 ANTIGEN; CA-19-9 ANTIGEN; CARCINOEMBRYONIC ANTIGEN; CARCINOMA, NON-SMALL-CELL LUNG; CARCINOMA, SQUAMOUS CELL; FEMALE; HUMANS; KERATINS; LUNG NEOPLASMS; MALE; MIDDLE AGED; NEOPLASM PROTEINS; NEOPLASM STAGING; PHOSPHOPYRUVATE HYDRATASE; PREDICTIVE VALUE OF TESTS; RETROSPECTIVE STUDIES; SENSITIVITY AND SPECIFICITY; SERPINS; TUMOR MARKERS, BIOLOGICAL;

EID: 0035171201     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (20)

1. Tumor markers in bronchogenic carcinoma. Superiority of tissue polypeptide antigen to carcinoembryonic antigen and carbohydrate antigenic determinant 19-9
2. Clinical of a multiple biomarker assay in patients with bronchogenic carcinoma
3. Comparison of cytokeratin fragment 19 (CYFRA21-1), tissue polypeptide antigen (TPA) and carcinoembryonic antigen (CEA) as tumour markers in bronchogenic carcinoma
4. Clinical evaluation of seven tumour markers in lung cancer diagnosis: Can any combination improve the results?
5. Cytokeratin 10 fragment CYFRA 21-1 compared with carcinoembryonic antigen, squamous cell carcinoma antigen and neuron-specific enolase in lung cancer: Results of an international multicenter study
6. Comparison of cytokeratin fragment 19 (CYFRA21-1), tissue polypeptide antigen (TPA), tissue polypeptide specific antigen (TPS) as tumour markers in lung cancer
7. The role of serum tumour markers to aid the selection of lung cancer patients for surgery and the assessment of prognosis
8. Serum fragment of cytokeratin subunit 19 measured by CYFRA 21-1 immunoradiometric assay as a marker of lung cancer
9. The new tumour marke CYFRA is superior to SCC antigen and CEA in the primary diagnosis of lung cancer
10. Clinical predictors of N2 disease in non-small cell lung cancer
11. Clinical predictors of N2 disease in the setting of a negative computed tomographic scan in patients with lung cancer
12. Prognostic value of preoperative carcinoembryonic antigen (CEA) plasma levels in patients with bronchogenic carcinoma
13. CEA, CYFRA21-1 and SCC in non-small cell lung cancer
14. Tumour markers CEA,NSE, SCC, TPA and CYFRA21.1 in resectable non-small cell lung cancer
15. CYFRA21-1 as a biologic marker of non-small cell lung cancer; elvaluation of sensitivity, specificity and prognostic role
16. Serum CA 125 level is a good prognostic indicator in lung cancer
17. Concordance between serum and cytosolic levels of CEA125 and SCC antigen in patients with non-small cell lung cancer
18. Evaluation of squamous cell carcinoma antigen (SCC-Ag) in the diagnosis and follow-up of patients with non-small cell lung carcinoma
19. Prognosis in bronchogenic squamous cell carcinoma groups divided according to serum squamous cell carcinoma-related antigen and cytokeratin 19 fragment levels